Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
NextCure Inc(NXTC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NXTC
11/10/2026: NXTC (1-star) is currently NOT-A-BUY. Pass it for now.
NextCure Inc is a clinical-stage biotechnology company developing immunomedicines for cancer using its proprietary FIND-IO discovery platform. The company's primary strength lies in its specialized research approach and experienced founding team, which positions it to address gaps in existing cancer immunotherapies. Its main growth opportunity involves successfully advancing its pipeline candidates through clinical trials and potentially securing high-value partnerships with larger pharmaceutical firms. However, investors must consider high execution risks, as clinical-stage biotech companies are prone to volatility and have no consistent revenue. The stock is best suited for risk-tolerant investors who monitor clinical trial updates as the primary indicator of company value and fundamental progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company represents a high-risk, high-reward play on innovative cancer research. |
| Momentum investor | Weak fit | Momentum depends on positive clinical trial data, which is infrequent and highly unpredictable. |
| Value investor | Weak fit | The company lacks stable earnings or dividends, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay a dividend and has no immediate plans to initiate one. |
| Low-risk investor | Weak fit | Biotechnology stocks are inherently volatile due to clinical failure risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience sharp price swings based on trial results. |
| Valuation risk | Medium / high | Valuations are speculative and based on the projected future success of drugs that may never reach the market. |
| Competition risk (oncology therapeutics) | High | The company faces immense competition from established firms with dominant market share in immuno-oncology. |
| Business quality | Medium | The company has a strong scientific foundation but lacks a proven commercial track record. |
| Dividend income | Low / none | There is no income generation for shareholders. |
| Execution risk | High | Success relies entirely on the complex and uncertain task of FDA clinical approval. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -68.36% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/10/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 28.71M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 63.6K shares | Beta 1.2 | 52 Weeks Range 1.55 - 15.74 | Updated Date 11/09/2026 |
52 Weeks Range 1.55 - 15.74 | Updated Date 11/09/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.99 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Research and Development | Collaborations, licensing deals, and future product commercialization. | The company does not currently generate meaningful revenue and burns cash to develop drugs. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8.67M | Price to Sales(TTM) 9.52 |
Enterprise Value 8.67M | Price to Sales(TTM) 9.52 | ||
Enterprise Value to Revenue 117.33 | Enterprise Value to EBITDA 0.51 | Shares Outstanding 4.58M | Shares Floating 2.92M |
Shares Outstanding 4.58M | Shares Floating 2.92M | ||
Percent Insiders 18.58 | Percent Institutions 54.36 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.